Nixon Capital’s Kyntra Bio KYNB Stock Holding History

Nixon Capital’s Portfolio KYNB Stock Details KYNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-291	Closed	-$2.9K	–	37
2024 Q3	$2.9K	Hold	291	–	–	﹤0.01%	32
2024 Q2	$6.49K	Hold	291	–	–	﹤0.01%	28
2024 Q1	$17.1K	Hold	291	–	–	0.01%	30
2023 Q4	$6.45K	Buy	+291	New	+$4.39K	﹤0.01%	24

Other funds holding KYNB

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Nixon Capital's KYNB Position: Q4 2024 in Review

Nixon Capital sold out of Kyntra Bio (KYNB) in Q4 2024, closing a stake of 291 shares — an estimated $2.9K sold.

Nixon Capital first reported a position in KYNB in Q4 2023 and held it in 4 quarters. The position peaked at $17.1K in Q1 2024. 68 funds tracked by Wall St. Rank hold KYNB as of Q4 2024.

Nixon Capital reported no remaining Kyntra Bio position as of Q4 2024 after selling out during the quarter.
Nixon Capital sold 291 Kyntra Bio shares in Q4 2024, an estimated $2.9K.
Nixon Capital first reported a position in Kyntra Bio in Q4 2023 and held it in 4 quarters.
Nixon Capital's Kyntra Bio position peaked at $17.1K in Q1 2024.
68 funds tracked by Wall St. Rank held Kyntra Bio as of Q4 2024.

Based on Nixon Capital's 13F filing for Q4 2024, filed 13 Feb 2025.